Bronstein, Gewirtz & Grossman, LLC Encourages Immunovant, Inc. (IMVT) Investors to Inquire about Securities Investigation
Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of investors in Immunovant, Inc. (IMVT) following a significant stock drop. This investigation comes after Immunovant announced on September 23, 2026, that its IMVT-1402 study for cutaneous lupus erythematosus failed to meet its primary endpoint, leading the company to halt further development of the drug for that indication. The firm is encouraging affected investors to inquire about the securities investigation through their website or by contacting them directly.
Immunovant, Inc. (IMVT) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation
Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Immunovant, Inc. (IMVT) after the company announced its proof-of-concept study for IMVT-1402 in cutaneous lupus erythematosus failed to achieve statistical significance, causing a 7.37% stock drop. The firm encourages investors to contact them to learn more about the investigation and potential class action lawsuit.
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Immunovant, Inc. (IMVT) and Encourages Stockholders to Learn More About the Investigation
Bronstein, Gewirtz & Grossman, LLC has announced an investigation into Immunovant, Inc. (IMVT) following a 7.37% stock price drop on September 23, 2026. This decline occurred after Immunovant's IMVT-1402 study for cutaneous lupus erythematosus failed to meet its primary endpoint, leading the company to halt further development for that indication. The law firm is encouraging investors who purchased Immunovant securities to join the investigation into potential claims.
Immunovant (IMVT): One Trial Failure Doesn’t Break the Bull Case
Immunovant (IMVT) experienced a setback with its IMVT-1402 trial for cutaneous lupus erythematosus (CLE), failing to meet its primary endpoint. Despite this, analysts believe the company's bull case remains intact due to five other ongoing IMVT-1402 programs for various autoimmune diseases, strong cash reserves, and increasing hedge fund interest. The company expects topline data from registrational trials in Graves’ disease and myasthenia gravis in 2027.
Immunovant CLO Christopher Van Tuyl Executes Mandatory Sale of 2,846 Shares for Tax Withholding
Christopher Van Tuyl, Immunovant's Chief Legal Officer, sold 2,846 shares of company common stock on September 23, 2026. This mandatory sale, at a weighted average price of $36.36 per share, was conducted to cover tax withholding obligations arising from the vesting of 6,872 restricted stock units (RSUs) on September 16, 2026. This transaction was non-discretionary and part of the issuer's "sell to cover" policy, leaving Van Tuyl with 176,545 directly owned shares.
IMVT Investor Alert: Levi & Korsinsky Investigates Immunovant, Inc. (IMVT) For Potential Securities Fraud
Levi & Korsinsky has launched an investigation into Immunovant, Inc. (NASDAQ:IMVT) for potential securities fraud following a significant 7.37% stock drop. The investigation comes after Immunovant announced that its lead drug candidate, IMVT-1402, failed to meet its primary endpoint in a proof-of-concept study for cutaneous lupus erythematosus, leading to the discontinuation of its development for that indication. The firm is inviting investors who experienced losses to explore potential recovery options.
Immunovant Investigation Notice: SueWallSt Notifies Investors of Pending Investigation Into Immunovant (IMVT)
SueWallSt, powered by Levi & Korsinsky LLP, has announced an investigation into Immunovant (IMVT) following a 6% stock drop on September 23, 2026. The decline occurred after Immunovant's IMVT-1402 cutaneous lupus study missed its primary endpoint, leading to the program's discontinuation. The investigation aims to determine if Immunovant made misleading statements regarding IMVT-1402's clinical prospects.
IMVT SHAREHOLDER INVESTIGATION: Levi & Korsinsky Investigates Immunovant, Inc. For Possible Securities Law Violations
Levi & Korsinsky LLP has launched an investigation into Immunovant, Inc. (NASDAQ:IMVT) for potential federal securities law violations after the company's shares dropped 7.37% on September 23, 2026. This follows the failure of a proof-of-concept study for IMVT-1402 in cutaneous lupus erythematosus, leading to the discontinuation of the drug's development for that indication. The firm is inviting investors who suffered losses to explore potential recovery options.
H.C. Wainwright Maintains Immunovant(IMVT.US) With Buy Rating, Maintains Target Price $41
H.C. Wainwright has reiterated its Buy rating for Immunovant (IMVT.US) and maintained its target price at $41. This indicates continued analyst confidence in the company's prospects.
Immunovant Pulls Plug On Lupus Program After Study Misses Primary Goal — IMVT Stock Heads For Over 3-Month Lows
Immunovant (IMVT) shares dropped after its lead drug candidate, IMVT-1402, failed to meet the primary endpoint in a study for cutaneous lupus erythematosus (CLE), leading the company to halt development for this indication. Despite positive trends in some measures, the results did not meet internal thresholds given the competitive landscape. Immunovant will continue to develop IMVT-1402 for other autoimmune diseases and expects its current cash reserves to fund operations through a potential launch in Graves' disease.
Why Is Immunovant Stock Falling Wednesday? - Roivant Sciences (NASDAQ:ROIV), Immunovant (NASDAQ:IMVT)
Immunovant Inc. (IMVT) announced it is discontinuing the development of IMVT-1402 for cutaneous lupus erythematosus (CLE) after the drug failed to meet its primary endpoint in a proof-of-concept trial. Despite positive safety trends, the company decided to shift focus to other autoimmune conditions due to insufficient clinical outcomes and the competitive landscape. This announcement led to a decline in stock prices for both Immunovant and its parent company, Roivant Sciences Ltd. (ROIV).
Immunovant drops cutaneous lupus program after IMVT‑1402 trial miss
Immunovant (NASDAQ: IMVT) is halting its cutaneous lupus development program after its Phase 2b trial for IMVT-1402, or imeroprubart, failed to meet its primary endpoint at Week 12. The study did not show a statistically significant difference in the CLASI-A score, though numerical trends favored treatment. Despite this setback, Immunovant will continue development for five other autoimmune indications, including Graves' disease and myasthenia gravis, with topline results expected in 2027.
Immunovant ends cutaneous lupus program after phase 2 flop
Immunovant has ceased development of its anti-FcRn antibody IMVT-1402 for cutaneous lupus erythematosus (CLE) after the drug failed to meet primary endpoints in a mid-phase trial. Although the company noted some numerical trends favoring the drug, the competitive landscape led them to discontinue the program in CLE. Immunovant plans to continue developing IMVT-1402 for other indications, including Graves’ disease and rheumatoid arthritis, where it showed a favorable safety profile.
Immunovant stock edges lower after recent clinical pipeline focus
Immunovant's stock experienced a slight decline, closing at $36.85, approximately 18% below its 52-week high, as investors re-evaluated biotech companies. The company is advancing its FcRn antibody IMVT-1402 through clinical trials for various autoimmune diseases, with potential commercial launches anticipated around 2028. Upcoming data readouts for indications like rheumatoid arthritis and cutaneous lupus are expected to be key catalysts for the stock.
Immunovant Q1 2027 Earnings Call: Complete Transcript
Immunovant (NASDAQ: IMVT) discussed its Q1 2027 financial results, reporting a quiet quarter but anticipating a busy second half with several key developments. These include the potential launch of brepocitinib for dermatomyositis, the initiation of a phase 3 study for brepocitinib in cutaneous sarcoidosis, and ongoing litigation. The company maintains a strong financial position with nearly $4 billion in cash and accelerated share repurchases, while strategically focusing on a slow and steady commercial approach for brepocitinib to build a foundation for future expansions.
Is Immunovant (IMVT) Undervalued After Its Pullback to $37.36?
Immunovant (IMVT) has experienced a recent stock pullback to $37.36, but it still shows a strong 1-year return of 140.6%. While short-term momentum is down, some analyses suggest the stock is undervalued, with a fair value estimate of $48.07, particularly given its pipeline, including IMVT-1402 for Graves' disease. However, its high P/B ratio compared to the biotech sector indicates significant optimism is already priced in, suggesting potential risks if trials disappoint.
Immunovant (IMVT) Stock Looks Expensive Based On Its Book Value
Immunovant's stock appears expensive based on its price-to-book (P/B) ratio, trading at 10.6x compared to the biotech industry average of 2.3x. Despite strong long-term returns and promising drug programs like imeroprubart for rheumatoid arthritis, analysts are questioning if the current valuation aligns with its book value. The article highlights both bull and bear case narratives, suggesting the stock could be undervalued by 22% or overvalued by 71% depending on future growth and competition.
Immunovant Announces Voting Outcomes from 2026 Annual Stockholders Meeting
Immunovant, Inc. has announced the voting results from its 2026 Annual Meeting of Stockholders. Key outcomes include the election of Jacob Bauer, Douglas Hughes, and Robert Susman to the Board of Directors, the ratification of Ernst & Young LLP as the independent auditor, and the approval of executive compensation in a non-binding advisory vote. Approximately 96% of voting shares were represented at the meeting.
Cantor Fitzgerald reiterates Immunovant stock Overweight rating
Cantor Fitzgerald maintained its Overweight rating on Immunovant (NASDAQ:IMVT) after reviewing the company's first-quarter earnings report, which led to an update in their financial model primarily for operating expenses. The stock has seen a significant 191% return over the past year, trading near its 52-week high, although InvestingPro data suggests it may be overvalued relative to its Fair Value estimate. Immunovant is a clinical-stage biopharmaceutical company focused on treatments for autoimmune diseases, and the Overweight rating implies an expectation of outperformance over the next 12-18 months.
UBS Adjusts Immunovant Price Target to $40 From $24, Maintains Neutral Rating
UBS has increased its price target for Immunovant (IMVT) to $40 from $24, while reiterating a Neutral rating on the stock. This adjustment reflects an updated valuation for the company.
Deep Track Capital, LP Trims Immunovant Inc (IMVT) Stake in Strategic Portfolio Adjustment
Deep Track Capital, LP significantly reduced its stake in Immunovant Inc (IMVT) by 18.96% on June 30, 2026, selling 2,185,820 shares at $38.53 each. This strategic move, which had a -1.38% impact on the firm's portfolio, still leaves Deep Track Capital with a substantial holding of 9,341,151 shares, representing 5.96% of its total portfolio. The adjustment reflects the healthcare-focused investment firm's active risk management, potentially locking in gains following Immunovant's stock appreciation, while maintaining long-term conviction in the clinical-stage immunology company.
Kuehn Law Encourages Investors of Immunovant, Inc. to Contact Law Firm
Kuehn Law, PLLC is investigating whether officers and directors of Immunovant, Inc. (NASDAQ: IMVT) breached their fiduciary duties to shareholders due to potential self-dealing. The firm is encouraging long-term IMVT stockholders to contact them, as they may be entitled to damages and corporate governance reforms. The consultation is free, and the firm covers all case costs.
Investigation launched into Immunovant officers for possible self-dealing harming shareholders
Kuehn Law, PLLC has initiated an investigation into potential breaches of fiduciary duties by officers and directors of Immunovant, Inc., citing possible self-dealing. This probe could lead to financial damages for shareholders and changes in the company's corporate governance. Long-term shareholders are encouraged to seek legal counsel promptly due to potential time limitations for action.
GSA Capital Partners LLP Takes $2.52 Million Position in Immunovant, Inc. $IMVT
GSA Capital Partners LLP has initiated a significant position in Immunovant, Inc. (NASDAQ:IMVT), purchasing 65,267 shares valued at approximately $2.52 million during the second quarter. This move comes as institutional investors and hedge funds collectively hold 47.08% of the company's stock, despite recent insider sales by the CTO and CEO to cover tax obligations. Analysts maintain a "Moderate Buy" consensus rating with an average price target of $44.00, while the company recently missed earnings per share estimates but met revenue forecasts.
Assenagon Asset Management S.A. Has $639,000 Holdings in Immunovant, Inc. $IMVT
Assenagon Asset Management S.A. significantly reduced its stake in Immunovant, Inc. (NASDAQ:IMVT) by 91.9% in the second quarter, selling 188,642 shares and retaining 16,577 shares valued at approximately $639,000. Despite this, institutional investors collectively own 47.08% of the company, and analysts generally maintain a "Moderate Buy" rating with an average price target of $44. The article also details other institutional investor activity, recent analyst ratings, stock performance, and insider trading.
Dimensional Fund Advisors LP Sells 103,356 Shares of Immunovant, Inc. $IMVT
Dimensional Fund Advisors LP significantly reduced its stake in Immunovant, Inc. (NASDAQ:IMVT) by selling 103,356 shares, retaining 57,086 shares valued at $1.42 million. This comes as Immunovant's insiders, including the CTO and COO, also sold a substantial number of shares recently. Analysts currently rate Immunovant as a "Moderate Buy" with a consensus price target of $44.00, despite the company reporting a wider-than-expected quarterly loss.
Immunovant stock hits 52-week high at 41.37 USD
Immunovant Inc.'s stock reached a 52-week high of $41.37, reflecting a 169% total return over the past year and strong investor confidence. Despite this, InvestingPro analysis suggests the stock might be overvalued relative to its Fair Value. Separately, Roivant Sciences, a related entity, reported an EPS miss due to increased R&D spending, though its stock remained near its 52-week high.
The Manufacturers Life Insurance Company Cuts Stock Position in Immunovant, Inc. $IMVT
The Manufacturers Life Insurance Company reduced its stake in Immunovant, Inc. (NASDAQ:IMVT) by 47.1% in the first quarter, selling over 45,000 shares but retaining 51,421 shares valued at $1.28 million. Despite this, other institutional investors have increased their positions. Immunovant reported a wider-than-expected quarterly loss of $0.75 per share, though revenue matched estimates, and analysts maintain a "Moderate Buy" rating with an average target price of $44.00, even as company insiders sold shares totaling over $11 million.
Immunovant, Inc. (NASDAQ:IMVT) Given Average Rating of "Moderate Buy" by Analysts
Immunovant, Inc. (NASDAQ:IMVT) has received an average recommendation of "Moderate Buy" from ten analysts, with an average twelve-month price target of $44.00. Recent analyst reports show several price target increases and "buy" ratings. Insider transactions indicate recent sales by the COO and CTO, while institutional investors have adjusted their holdings, with some significantly increasing their stakes.
Liquidity Mapping Around (IMVT) Price Events
This article provides a liquidity mapping analysis for Immunovant Inc. (NASDAQ: IMVT), highlighting a near-term strong sentiment transitioning to mid-term neutrality and long-term positive bias. It details three AI-generated trading strategies—Position Trading, Momentum Breakout, and Risk Hedging—with specific entry, target, and stop-loss levels. The analysis also includes multi-timeframe signal analysis, identifying key support and resistance levels.
Hennion & Walsh Asset Management Inc. Has $4.65 Million Stock Holdings in Immunovant, Inc. $IMVT
Hennion & Walsh Asset Management Inc. significantly increased its stake in Immunovant, Inc. (NASDAQ:IMVT) by 32.6% in the second quarter, now holding 120,686 shares valued at $4.65 million. Despite this institutional confidence and a "Moderate Buy" consensus rating from analysts, Immunovant reported a wider-than-expected quarterly loss of $0.75 per share, and company insiders have sold substantial shares recently.
Renaissance Technologies LLC Invests $4.78 Million in Immunovant, Inc. $IMVT
Renaissance Technologies LLC has acquired a new stake of $4.78 million in Immunovant, Inc. (NASDAQ:IMVT), while institutional investors collectively own 47.08% of the company's stock. Despite analysts maintaining a "Moderate Buy" rating with an average target price of $44, Immunovant insiders have sold approximately $11.35 million in shares over the past three months, and the company recently missed quarterly EPS estimates. Immunovant is a clinical-stage biopharmaceutical company focusing on novel monoclonal antibody therapies for autoimmune diseases.
Immunovant, Inc. Q1 2027: Net loss $153.2M, EPS $(0.75) — 10-Q Summary
Immunovant, Inc. reported a net loss of $153.2 million for Q1 2027, an increase from $120.6 million in the prior year, with diluted loss per share at $(0.75). The company generated no revenues for the quarter and is focusing on the development of IMVT-1402 across multiple indications following the discontinuation of batoclimab. All IMVT-1402 studies are utilizing the commercial formulation and YpsoMate® autoinjector, with manufacturing contracts in place for clinical trials and potential launch.
Immunovant, Inc. Stock 12‑Month Price Target Raised to $47.56, Implies 21% Upside
Immunovant, Inc.'s stock price target has been increased to $47.56 from $47.06 by 16 analysts, implying a 21% potential upside based on its Aug. 5 closing price. The consensus rating remains "Buy," with 12 analysts recommending Buy and 4 recommending Hold.
Immunovant's Q1 Loss Wider Than Expected, Pipeline in Progress
Immunovant (IMVT) reported a wider-than-expected net loss of 75 cents per share in Q1 fiscal 2027, surpassing the Zacks Consensus Estimate of a 66-cent loss. Despite no approved products, the company is advancing its lead asset, IMVT-1402, an FcRn inhibitor, through multiple clinical trials for various autoimmune indications like Graves' disease and myasthenia gravis, with key data readouts anticipated in 2026 and 2027. Research and development expenses increased due to these clinical studies, but the company's cash reserves are projected to fund operations through the commercial launch of IMVT-1402 for Graves' disease.
Immunovant reports $153.2M net loss, $797.8M cash as of June 30, 2026
Immunovant reported a net loss of $153.2 million and held $797.8 million in cash as of June 30, 2026. The company's R&D expenses increased, while G&A expenses decreased. Immunovant confirmed that the clinical development timelines for IMVT-1402 across six indications remain on track, with potential registrational data expected through 2028, and a sufficient cash runway for the commercial launch of IMVT-1402 in Graves' disease.
Immunovant Provides Corporate Updates and Reports Financial Results for the Quarter Ended June 30, 2026
Immunovant (Nasdaq: IMVT) announced its corporate updates and financial results for the first fiscal quarter ended June 30, 2026. The company's IMVT-1402 clinical development timelines remain on track across six indications, with topline data expected for various trials between calendar years 2026 and 2028. Immunovant reported a cash balance of $797.8 million, sufficient to fund operations through the potential launch of IMVT-1402 in Graves' disease.
Immunovant's $797.8M Cash Provides Runway to Potential Drug Launch
Immunovant (IMVT) reported its fiscal first-quarter 2026 financial results, including a net loss of $153.2 million and R&D expenses of $142.6 million. Despite increased R&D, the company's cash and cash equivalents of $797.8 million as of June 30, 2026, are projected to provide sufficient funding for the potential commercial launch of its IMVT-1402 drug for Graves’ disease. Immunovant confirmed that all clinical development timelines for IMVT-1402 across six indications remain on track, with key data readouts anticipated between late 2026 and 2028.
Earnings Flash (IMVT) Immunovant Posts Fiscal Q1 Loss $0.75 a Share, vs. FactSet Est of $0.65 Loss
Immunovant (IMVT) reported a fiscal Q1 loss of $0.75 per share, which is wider than the FactSet estimate of a $0.65 loss per share. The company is a clinical-stage immunology company focused on developing targeted therapies for autoimmune diseases. Its pipeline includes product candidates IMVT-1402 and batoclimab, targeting the neonatal FcRn.
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Immunovant, Inc. f/k/a Health Sciences Acquisitions Corporation of Class Action Lawsuit and Upcoming Deadline - IMVT; HSACU; HSAC; and HSACW
Pomerantz LLP has filed a class action lawsuit against Immunovant, Inc. (formerly Health Sciences Acquisitions Corporation) and some of its officers, seeking to recover damages for investors who purchased Immunovant securities between October 2, 2019, and February 1, 2021. The lawsuit alleges that Immunovant made materially false and misleading statements regarding its business, operations, and compliance policies, particularly concerning the safety and prospects of its drug candidate IMVT-1401, leading to a significant stock price drop. Shareholders who incurred losses have until April 20, 2021, to seek appointment as Lead Plaintiff.
Perceptive Advisors LLC Lowers Stake in Immunovant, Inc. $IMVT
Perceptive Advisors LLC reduced its stake in Immunovant, Inc. (NASDAQ:IMVT) by 19.9% in the first quarter of 2026, selling 397,507 shares but still retaining 1.60 million shares valued at approximately $39.7 million. Despite this, institutional investors collectively own 47.08% of the company. Immunovant shares opened at $38.62, near their 52-week high, while the company reported a larger-than-expected quarterly loss of $0.73 per share.
IMVT Maintained by JP Morgan -- Price Target Raised to $50.00
JP Morgan has maintained an Overweight rating on Immunovant (IMVT), increasing its price target to $50.00 from $47.00. Despite this positive analyst outlook, Immunovant holds a low GF Score™ of 29/100, indicating challenges in profitability and growth, and has seen significant insider selling. The company, a clinical-stage immunology firm, is focused on developing therapies for autoimmune diseases.
Immunovant (IMVT) Stock Forum and Discussion
This page provides a stock forum and discussion platform for Immunovant (IMVT). It allows investors and interested parties to share insights, opinions, and analysis related to the company's stock performance and future prospects. The forum serves as a community hub for active engagement on IMVT.
Immunovant (IMVT.US) will release its earnings report before the market opens on August 6.
Immunovant (IMVT.US) is scheduled to release its earnings report before the market opens on August 6. This announcement provides key information for investors and stakeholders anticipating the company's financial performance.
Immunovant (Nasdaq:IMVT) - Stock Analysis
This Simply Wall St analysis of Immunovant (IMVT) provides an overview of the company's financial health, future growth prospects, past performance, and insider transactions. It highlights the company's focus on developing targeted therapies for autoimmune diseases, particularly IMVT-1402, and discusses recent news, analyst ratings, and risks associated with the stock.
Why (IMVT) Price Action Is Critical for Tactical Trading
This article provides a critical analysis of Immunovant Inc. (IMVT) stock's price action for tactical trading, highlighting neutral near and mid-term readings but a positive long-term bias. It outlines distinct AI-generated trading strategies—Position, Momentum Breakout, and Risk Hedging—with specific entry, target, and stop-loss levels. The analysis also includes multi-timeframe signal strengths, support, and resistance levels to guide trading decisions.
Immunovant, Inc. Revenue Breakdown – NASDAQ:IMVT
This page provides financial overview for Immunovant, Inc. (NASDAQ: IMVT). It indicates that the market is closed with no trades. The article is primarily a navigation and information hub for financial data on Immunovant, Inc., mentioning sections like "Fundamentals and stats," "Overview," "Statements," "Statistics," and "Dividends."
Immunovant Inc (IMVT) Dividends & Stock Splits: Historical Payouts and Event Timeline
This article provides an overview of Immunovant Inc (IMVT)'s dividend and stock split history. It states that the company has distributed a total of $0.00 in dividends over the past five years, indicating no recent dividend payouts. The page also presents other financial data like the stock price, market cap, and P/E TTM.
Immunovant Inc (IMVT) Cash Flow
This article provides a detailed cash flow statement for Immunovant Inc (IMVT), covering quarterly and annual data for operating, investing, and financing activities. It presents financial figures such as net income, capital expenditures, and free cash flow, alongside year-over-year percentage changes. The article also includes a FAQ section defining different types of cash flow and their significance for investors.
Immunovant Inc (IMVT) Shareholder Structure: Major Shareholders & Institutional Holdings
This article details the shareholder structure of Immunovant Inc (IMVT), listing major shareholders and their respective proportions, along with a breakdown by shareholder types. It also provides institutional shareholding data over several quarters and an overview of related ETF holdings. Key holders include Roivant Sciences Ltd., Fidelity Management & Research Company LLC, and Deep Track Capital LP.
